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Q INTRODUCTION 
Tuberculosis (TB) is a disease caused by a germ called Mycobacterium tuberculosis (MTB) that is 
spread from person to person through the air. Per-
sons inhaling air containing these droplet nuclei 
may become infected. 
The infection does not determine TB disease as 
ever. As a result, two TB-related conditions ex-
ist: latent TB infection (LTBI) and TB disease. A 
person with latent TB infection is described as 
following:
– Usually has a skin test or blood test result indi-
cating TB infection.
– Has a normal chest X-ray and a negative spu-
tum test.
– Has TB bacteria in his/her body that are alive, 
but inactive.
– Does not feel sick.
– Cannot spread TB bacteria to others.
– Needs treatment for latent TB infection to 
prevent TB disease; however, if exposed and 
infected by a person with multidrug-resistant 
TB (MDR TB) or extensively drug-resistant TB 
(XDR TB), preventive treatment may not be an 
option.
About 5 to 10% of infected persons will devel-
op TB disease at some time in their lives (rein-
fection), mostly within the first two years of 
infection. The risk of developing TB disease is 
considerably higher for persons whose immune 
systems are weak. 
Since almost one third of the world population is 
infected by MTB, LTBI is the source of most future 
TB disease so that the strategies to eliminate TB in 
industrialized countries hinge on diagnosis and 
treatment of LTBI. 
O’Connor in the far 1940 stated: “… is it better to 
have a positive or negative tuberculin test? Show 
me the student who has not asked this question. I 
might add, show me the physician who can give 
an unequivocal answer …” [1].
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Screening of latent infection by Mycobacterium 
tuberculosis (LTBI) and treatment of positive subjects 
is the key point in the prevention of TB; such a strategy 
should be performed mainly among individuals with 
risk of progression. Progression from LTBI to active TB 
is highest both in recent contacts of patients with active 
TB, and in immunocompromised subjects. Therefore, 
LTBI could either be considered a permanent host 
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defence or, seen from the opposite point of view, it 
could represent a long-lasting threat if the efficiency of 
the immune system declines over a lifetime. Interferon 
gamma release assays (IGRAs) show better sensitivity 
and specificity than the Mantoux test.
Keywords: active tuberculosis, latent tuberculosis 
infection, interferon gamma release assays.
180 A. Sanduzzi, et al.
Q IMMUNOLOGY
Still today, we do understand neither what consti-
tutes a protective immune response to TB in the 
lung nor the extent to which the phenotype of an-
tigen-specific CD4+ T cells contributes to this pro-
tective response. Another potential confounder 
is that MTB is able to manipulate both the innate 
and acquired immune response of the host so that 
the result can be an effective CD4+ T cell response 
limiting the disease but it can also promote the 
development of progressively destructive lesions 
in the lung [2].
A plausible working model is that MTB initiates 
recruitment of permissive phagocytes into the 
lung, limiting the recruitment of T cells capable 
of redirecting the permissive phagocytes to a bac-
tericidal state, resulting in a permissive environ-
ment wherein the bacterium can grow without 
significant barriers.
Cellular immune responses to Mycobacterium tu-
berculosis progress in two stages. First, initial in-
nate immunity involves the direct production of 
cytokines, such as tumor necrosis factor (TNF), in-
terleukin-12 (IL-12) and others, by infected mac-
rophages activated via toll-like and other pattern 
receptors [3].
Later, such mechanisms are amplified by adap-
tive responses of pathogen-specific T lympho-
cytes recruited to the site of infection, leading 
to the production of interferon gamma (IFNќ), 
useful both to amplify the immunological re-
sponse and to activate intracellular antibacteri-
al mechanisms [4]. Therefore, the early macro-
phage-T-cell interactions result in inhibition of 
mycobacterial growth, and lead to the forma-
tion of granuloma.
The tubercle bacilli enter the body via the respira-
tory route. The bacilli spread from the site of ini-
tial infection in the lung through the lymphatics 
or through the blood to other parts of the body. 
LTBI is the result of inhalation of MTB, if bacte-
rial load is high and/or immune host defense is 
not adequate. Infection develops in 40-90% of 
subjects exposed to even isolated contact. Within 
a couple of years from the contact, infection can 
cause overt disease in 5-10% of infected subjects, 
remaining latent in 90-95%, owing to capacity of 
immune system of limiting MTB growth. After 
the first two years from the contact, LTBI can be-
come active, causing overt disease in 0.1-0.5% of 
infected subjects per year. This is the lifetime year 
risk for tuberculosis. 
From a first point of view, we can consider LTBI 
a permanent threat. Risk factors for progression 
of infection to active tuberculosis (reinfection) are:
– human immunodeficiency virus (HIV) infec-
tion;
– infants and children aged <5 years and per-
sons aged >75 years;
– immunosuppressive therapy such as tumor 
necrosis factor-alpha (TNF-_) antagonists, 
systemic corticosteroids equivalent to ≥15 mg 
of prednisone per day, or immune suppressive 
drug therapy following organ transplantation; 
– recent infection with M. tuberculosis (within 
the past 2 years); 
– history of untreated or inadequately treated 
active tuberculosis (including persons with fi-
brotic changes on chest radiograph consistent 
with prior active tuberculosis); 
– silicosis, diabetes mellitus, chronic renal fail-
ure, leukemia, lymphoma, or cancer of the 
head, neck, or lung; 
– gastrectomy or jejunoileal bypass; 
– weight <90% of their ideal body weight; 
– cigarette smokers and drugs or alcohol abuse 
– populations defined locally as having an in-
creased incidence of active tuberculosis, pos-
sibly including medically underserved or 
low-income populations.
In particular tobacco smoking and chronic ob-
structive pulmonary disease COPD) are very 
common and important risk factors that cause 
increased susceptibility to chronic subclinical in-
fections, aberrant inflammatory response, and al-
tered oxidant-antioxidant balance [5, 6].
It is now recognized that TNF mAbs represent a 
high risk for reactivation of LTBI, which, if un-
treated, produces Tb reactivation rates many times 
more that in the general population [7]. Most of 
that risk is concentrated in the first few months 
of anti-TNF treatment, suggesting that the subse-
quent decline of incidence of TB cases could be due 
to depletion of “reactivatable” LTBI [8].
From the opposite point of view, Andrews et al. 
studied two prospective cohorts of persons ex-
posed to patients with infectious tuberculosis, to 
estimate the incidence of tuberculosis among in-
dividuals with latent tuberculosis infection (LTBI 
group) and without latent tuberculosis (uninfect-
ed). Individuals with latent tuberculosis had 79% 
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lower risk of progressive tuberculosis after rein-
fection than uninfected individuals. What comes 
from such a study could lead to the conclusion that 
LTBI could represent a permanent defense [9].
Q DIAGNOSIS
Nowadays, the gold standard test to diagnose 
latent tubercular infection is still Mantoux test, 
which is more than 100 years old and presents 
some limitations: 
– measures a single antigen;
– can induce a boosting effect; 
– it’s necessary a second visit;
– there is an inter-operator variability; 
– result comes out in 48-72 h.
In the last ten years, interferon gamma release as-
says (IGRA) tests have shown a higher sensitivity 
and specificity than tuberculin test (9-13). IGRAs 
advantages are numerous:
– are an in vitro test;
– measure multiple antigens, particularly those 
related to cell mediated immune response to 
different polypeptides, as ESAT-6, CFP-10, 
TB7.7;
– do not induce boosting effect;
– it’s not necessary a second visit;
– no (or minimal) inter-operator variability; 
– result in 24 h;
– recently, Quantiferon Gold® plus seems to 
measure additional peptides in which there 
are epitopes recognized by CD8 T-lympho-
cytes, potentially contributing to identify ac-
tive tuberculosis more than latent infection, re-
cent exposure more than ancient one, infection 
even in immunocompromised subjects (HIV) 
or in children under 5 yrs.
Considering such advantages, as a whole, IGRA 
tests are very useful in order to detect LTBI, more 
than Mantoux test, but do not perform to monitor 
treatment both of latent infection, and of active 
disease [10].
Q CONCLUSIONS
In conclusion, LTBI can be considered both a de-
fense mechanism and a threat potentially danger-
ous for the subject: the cut-off between the two 
possibilities has to be identified in the integrity 
of immune system. LTBI per se is undoubtedly a 
protective entity, representing the complex strate-
gy of host, set up in response to tubercular infec-
tion, finalized to contain the spread of bacilli. At 
any phase of life, the effectiveness of host defense 
can decrease, owing to chronic disease, cancers, 
advanced age, immunosuppressive drugs or im-
munocompromising disease, to such a level, that 
residual, low-viable M. tuberculosis strains can 
escape granulomas and disseminate the whole 
organism, overcoming also other innate immune 
defenses, like NK cells, a strong protection, like in 
several pulmonary disease [14, 15].
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